- Home
- SIGA vs AQST Comparison
SIGA vs AQST Comparison
Compare SIGA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- AQST
- Stock Information
- Founded
- SIGA 1995
- AQST 2004
- Country
- SIGA United States
- AQST United States
- Employees
- SIGA N/A
- AQST N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- AQST Health Care
- Exchange
- SIGA Nasdaq
- AQST Nasdaq
- Market Cap
- SIGA 551.0M
- AQST 502.6M
- IPO Year
- SIGA 1997
- AQST 2018
- Fundamental
- Price
- SIGA $6.27
- AQST $4.51
- Analyst Decision
- SIGA
- AQST Strong Buy
- Analyst Count
- SIGA 0
- AQST 7
- Target Price
- SIGA N/A
- AQST $9.43
- AVG Volume (30 Days)
- SIGA 546.7K
- AQST 1.7M
- Earning Date
- SIGA 11-07-2024
- AQST 11-04-2024
- Dividend Yield
- SIGA 9.64%
- AQST N/A
- EPS Growth
- SIGA N/A
- AQST N/A
- EPS
- SIGA 1.20
- AQST N/A
- Revenue
- SIGA $173,731,386.00
- AQST $58,900,000.00
- Revenue This Year
- SIGA $16.98
- AQST $18.45
- Revenue Next Year
- SIGA $16.49
- AQST N/A
- P/E Ratio
- SIGA $5.21
- AQST N/A
- Revenue Growth
- SIGA 399.31
- AQST 22.56
- 52 Week Low
- SIGA $4.26
- AQST $1.84
- 52 Week High
- SIGA $12.83
- AQST $6.23
- Technical
- Relative Strength Index (RSI)
- SIGA 38.27
- AQST 40.86
- Support Level
- SIGA $6.02
- AQST $4.36
- Resistance Level
- SIGA $7.89
- AQST $4.88
- Average True Range (ATR)
- SIGA 0.45
- AQST 0.37
- MACD
- SIGA -0.09
- AQST -0.07
- Stochastic Oscillator
- SIGA 17.87
- AQST 12.20
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.